Fortress Biotech, Inc. (FBIO)
FBIO Stock Price Chart
Explore Fortress Biotech, Inc. interactive price chart. Choose custom timeframes to analyze FBIO price movements and trends.
FBIO Company Profile
Discover essential business fundamentals and corporate details for Fortress Biotech, Inc. (FBIO) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
17 Nov 2011
Employees
101.00
Website
https://www.fortressbiotech.comCEO
Lindsay Allan Rosenwald
Description
Fortress Biotech, Inc. operates as a biopharmaceutical firm dedicated to the development and commercialization of a diverse range of pharmaceutical and biotechnology products. The company currently offers a portfolio of dermatological treatments. These include Ximino and Targadox, both formulated to address various forms of acne (ranging from moderate-to-severe inflammatory lesions to severe cases). Other products in this segment are Exelderm cream for fungal skin infections like ringworm and jock itch, Ceracade for dry skin conditions, Luxamend for wound care, and Accutane capsules for particularly severe, stubborn nodular acne. Its pipeline features several promising late-stage drug candidates, targeting a diverse range of medical needs. These include intravenous Tramadol for acute post-operative pain, CUTX-101 (an injection for Menkes disease), MB-107 and MB-207 for X-linked severe combined immunodeficiency, Cosibelimab for metastatic cancers, CK-101 for non-small cell lung cancer characterized by EGFR mutations, CAEL-101 for amyloid light chain (AL) amyloidosis, the Triplex vaccine for cytomegalovirus, and CEVA101 for critical traumatic brain injuries in adults and children. Furthermore, its earlier-stage research encompasses various investigational treatments such as MB-102 for blastic plasmacytoid dendritic cell neoplasm, MB-101 for glioblastoma, MB-104 for multiple myeloma and light chain amyloidosis, MB-106 for B-cell non-Hodgkin lymphoma, MB-103 for glioblastoma and metastatic breast cancer to the brain, MB-108, MB-105 for prostate and pancreatic malignancies, and BAER-101. In the preclinical phase, Fortress Biotech is exploring an array of novel therapeutic approaches. These comprise AAV-ATP7A and AVTS-001 (both gene-based therapies), the CK-103 BET inhibitor, CEVA-D and CEVA-102, CK-302 (an antibody targeting GITR), CK-303 (an antibody against CAIX), ConVax, and the ONCOlogues oligonucleotide platform. The company also actively engages in collaborative ventures with universities, research institutions, and other pharmaceutical organizations. Originally established in 2006, the entity operated as Coronado Biosciences, Inc. before rebranding as Fortress Biotech, Inc. in April 2015. Its corporate headquarters are situated in Bay Harbor Island, New York.
FBIO Financial Timeline
Browse a chronological timeline of Fortress Biotech, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 13 Aug 2026
EPS estimate is -$0.20, while revenue estimate is $18.30m.
Earnings released on 14 May 2026
EPS came in at $2.82 surpassing the estimated -$0.22 by +1.38k%, while revenue for the quarter reached $16.04m , missing expectations by -1.84%.
Earnings released on 31 Mar 2026
EPS came in at -$0.21 falling short of the estimated $0.42 by -150.00%, while revenue for the quarter reached $16.08m , missing expectations by -38.55%.
Earnings released on 14 Nov 2025
EPS came in at $0.11 surpassing the estimated -$0.43 by +125.58%, while revenue for the quarter reached $17.63m , missing expectations by -16.12%.
Earnings released on 14 Aug 2025
EPS came in at -$0.46 falling short of the estimated -$0.31 by -48.39%, while revenue for the quarter reached $16.41m , missing expectations by -21.91%.
Earnings released on 21 May 2025
EPS came in at -$1.03 falling short of the estimated -$0.44 by -134.09%, while revenue for the quarter reached $13.14m , beating expectations by +13.07%.
Earnings released on 27 Mar 2025
EPS came in at -$0.53 surpassing the estimated -$0.79 by +32.91%, while revenue for the quarter reached $15.12m , missing expectations by -7.22%.
Earnings released on 14 Nov 2024
EPS came in at -$0.76 falling short of the estimated -$0.27 by -181.48%, while revenue for the quarter reached $14.63m , missing expectations by -6.08%.
Earnings released on 13 Aug 2024
EPS came in at -$0.73 surpassing the estimated -$1.32 by +44.70%, while revenue for the quarter reached $14.90m , beating expectations by +0.85%.
Earnings released on 15 May 2024
EPS came in at -$1.03 surpassing the estimated -$2.03 by +49.26%, while revenue for the quarter reached $13.03m , missing expectations by -7.78%.
Earnings released on 28 Mar 2024
EPS came in at -$0.53 surpassing the estimated -$1.97 by +73.10%, while revenue for the quarter reached $19.95m , beating expectations by +33.96%.
Earnings released on 14 Nov 2023
EPS came in at -$0.94 surpassing the estimated -$3.53 by +73.37%, while revenue for the quarter reached $34.75m , beating expectations by +117.88%.
Stock split effective on 10 Oct 2023
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Aug 2023
EPS came in at -$3.60 surpassing the estimated -$3.90 by +7.69%, while revenue for the quarter reached $17.39m , missing expectations by -0.42%.
Earnings released on 15 May 2023
EPS came in at -$3.15 falling short of the estimated -$2.85 by -10.53%, while revenue for the quarter reached $12.43m , missing expectations by -38.68%.
Earnings released on 30 Mar 2023
EPS came in at -$4.50 falling short of the estimated -$3.30 by -36.36%, while revenue for the quarter reached $16.40m , missing expectations by -25.61%.
Earnings released on 14 Nov 2022
EPS came in at -$3.75 surpassing the estimated -$4.05 by +7.41%, while revenue for the quarter reached $16.53m , missing expectations by -20.68%.
Earnings released on 11 Aug 2022
EPS came in at -$3.60 falling short of the estimated -$3.00 by -20.00%, while revenue for the quarter reached $18.89m , missing expectations by -17.08%.
Earnings released on 12 May 2022
EPS came in at -$2.70 surpassing the estimated -$4.20 by +35.71%, while revenue for the quarter reached $23.93m , beating expectations by +19.22%.
Earnings released on 28 Mar 2022
EPS came in at -$5.70 falling short of the estimated $1.50 by -480.00%, while revenue for the quarter reached $18.28m , missing expectations by -53.90%.
Earnings released on 15 Nov 2021
EPS came in at -$3.90 falling short of the estimated -$1.20 by -225.00%, while revenue for the quarter reached $21.09m , beating expectations by +7.74%.
Earnings released on 16 Aug 2021
EPS came in at -$0.60 surpassing the estimated -$2.10 by +71.43%, while revenue for the quarter reached $17.84m , missing expectations by -3.13%.
FBIO Stock Performance
Access detailed FBIO performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
